Multiple clinical trials are ongoing in breast cancer and other HER2-expressing cancers, evaluating promising novel drug formats, including (combinations of) HER2-targeted bispecific antibodies, ADCs, radiotherapies, and cancer vaccines [7,8]. Here, ERBB2 is linked to cancer.